DPP9 and nonpapillary renal cell carcinoma: Therefore, for patients with DPP9-overexpressing resistant ccRCC, it might be possible to attempt reversing targeted therapy resistance by using small-molecule compounds to block the interaction between DPP9 and KEAP1, thereby inhibiting the excessive activation of NRF2 signaling.